Article Information
History
- March 16, 2022.
Article Versions
- You are currently viewing Version 1 of this article (March 16, 2022 - 17:54).
- Version 2 (June 30, 2022 - 07:43).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Catherine Hyams1,2,*,
- David T Arnold1,
- Robyn Heath2,
- Zahin Amin-Chowdhury5,
- David Hettle3,4,
- Gabriella Ruffino1,
- Paul North3,4,
- Charlotte Grimes1,
- Norman K Fry5,
- Philip Williams3,4,
- Leon Danon6,
- O Martin Williams3,4,
- Shamez Ladhani5,
- Adam Finn6 and
- Nick A Maskell1
- 1Academic Respiratory Unit, Learning and Research, Southmead Hospital, Bristol BS10 5NB, United Kingdom
- 2Vaccine and Testing Research Team, Clinical Research Facility, St Michael’s Hill, Bristol Royal Infirmary, Bristol, United Kingdom
- 3Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
- 4Department of Microbiology, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK, BS2 8HW
- 5National Infection Service, UKHSA, London, United Kingdom
- 6Engineering Mathematics, University of Bristol, Bristol, United Kingdom
- 7Bristol Vaccine Centre, Schools of Cellular and Molecular Medicine and of Population Health Sciences, University of Bristol, Bristol, BS2 8AE, United Kingdom
- ↵*Corresponding address:
Dr Catherine Hyams, MBBS BSc(Hons) PhD MRCP, Academic Respiratory Unit, Learning & Research Building, Southmead Hospital, Bristol, BS10 5NB, catherine.hyams{at}bristol.ac.uk
Posted March 16, 2022.
Parapneumonic effusions related to Streptococcus pneumoniae: serotype and disease severity trends
